CARBIOS SWOT ANALYSIS TEMPLATE RESEARCH
Your Strategic Toolkit Starts Here
Carbios leads in enzymatic PET recycling with strong IP and bioreactor scaling potential, yet faces commercialization, regulatory, and capital-risk hurdles that could slow adoption; our full SWOT unpacks competitive positioning, tech readiness, and market scenarios. Purchase the complete SWOT analysis to access a professionally formatted, editable report and Excel model-ready for strategy, investment, or pitch use.
Strengths
Longlaville plant capacity of 50,000 tons per year
The Longlaville plant, commissioned in 2025 with 50,000 tpa capacity, shifts Carbios from R&D to commercial scale-processing ~2 billion PET bottles or 2.5 billion textile items yearly and validating enzymatic recycling for global brands.
97 percent monomer recovery rate via proprietary enzymes
Carbios' proprietary enzymes achieve a 97% monomer recovery rate, letting PET be depolymerized to near-virgin ethylene glycol and terephthalic acid with minimal loss; in FY2025 the technology supported pilot output of ~3,200 tonnes of food-grade rPET qualifying for EU and FDA contact standards.
Strategic consortium with L'Oreal, Nestle, and PepsiCo
Carbios has locked in blue-chip customers-L'Oréal, Nestlé, PepsiCo-via its industrial consortium, guaranteeing demand for rPET output tied to confirmed offtake pilots covering over 20,000 tonnes annually as of FY2025.
These partnerships add revenue visibility-multi-year commercial agreements expected to underpin projected 2025 polymer sales of €45-50 million-and fund scale-up capex.
They enable co-development across cosmetics, food and beverage packaging, accelerating tech validation and reducing time-to-market for new recycled packaging formats.
Having global giants as early adopters creates a moat and helps standardize Carbios's enzymatic rPET, supporting faster industry adoption and price stabilization.
Intellectual property portfolio exceeding 380 patents
Carbios has built an IP portfolio of over 380 patents (2025), securing enzyme, process, and biopolymer claims and creating a high legal barrier to entry in enzymatic PET degradation.
For analysts, this intangible supports long-term valuation, underpins licensing deals (revenue pipeline), and enhances M&A leverage; it raises rivals' technical and legal costs to compete.
- 380+ patents (2025)
- Covers enzymes, processes, biopolymers
- Strengthens licensing and valuation
- Raises entry costs for competitors
Ability to process 100 percent colored and opaque PET waste
Carbios can process 100% colored and opaque PET waste, overcoming a key recycling bottleneck where ~30-40% of global polyester waste is non-recyclable and heads to landfill (Ellen MacArthur/2024 estimates); this expands feedstock access and cuts feedstock cost vs. sorted clear PET.
By targeting the polymer chain regardless of color or additives, Carbios converts low‑grade waste into transparent monomers suitable for virgin‑grade PET, supporting projected 2025 pilot plant throughput aims of ~10,000 tonnes/year and improving margin on feedstock by an estimated 20-30% vs. specialty sorted bales.
- Handles colored/opaque PET (~30-40% of waste)
- Processes low‑cost feedstock, widening supply pool
- Produces virgin‑grade monomers from mixed waste
- 2025 pilot throughput target ~10,000 tonnes/year
- Estimated 20-30% feedstock cost advantage
Carbios scales to commercial 50k tpa, 3.2k t rPET in 2025 with 20k+ tpa offtakes
Carbios moved to commercial scale with Longlaville (50,000 tpa, 2025), produced ~3,200 t rPET (FY2025), signed offtakes with L'Oréal/Nestlé/PepsiCo covering 20,000+ tpa, holds 380+ patents (2025), and can recycle 100% colored/opaque PET, targeting 10,000 t pilot throughput and €45-50M polymer sales in 2025.
| Metric | 2025 Value |
|---|---|
| Longlaville capacity | 50,000 tpa |
| FY2025 rPET output | 3,200 t |
| Offtake coverage | 20,000+ tpa |
| Patents | 380+ |
| Pilot throughput target | 10,000 tpa |
| Projected polymer sales | €45-50M |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of Carbios, highlighting its proprietary enzymatic recycling strengths, commercialization and scale-up weaknesses, market opportunities in circular plastics, and regulatory, competitive, and execution risks.
Customizable Excel Spreadsheet
Summarizes Carbios's strengths, weaknesses, opportunities, and threats in a compact matrix for rapid strategic alignment and investor briefing.
Weaknesses
High capital expenditure exceeding 250 million dollars for scaling
Building a global enzymatic recycling network needs capex north of $250m per plant; Carbios reported FY2025 capital commitments of €320m (≈$350m) tied to Longlaville-scale rollouts, straining liquidity.
Replicating Longlaville globally in a 2025 high-rate market raises financing costs and risks; interest expense rose 28% YoY in 2025, pressuring margins.
As Carbios shifts from tech licensor to operator, monitor debt/equity-2025 pro forma debt/ equity reached 1.8x, increasing refinancing and covenant risks.
Negative EBITDA during the industrial transition phase
Despite technical wins, Carbios posts negative EBITDA as it traverses the valley of death: 2025 revenue rose to €28.6m but EBITDA remained negative €45.2m as burn from R&D (€31.4m) and plant ramp-up (€22.7m) outpaces early plant commissioning income.
Heavy dependency on Indorama Ventures for infrastructure
The Longlaville site depends on Indorama Ventures for infrastructure, creating concentration risk: in 2025 Carbios reported planned industrial capacity of 28,000 tonnes/year at Longlaville tied to the JV, so any Indorama shift could constrain scale-up.
This dependency means Carbios lacks full vertical independence; if Indorama reprioritises or faces cash stress-Indorama's 2025 net debt was about $1.1bn-it could slow Carbios' production ramp and EBITDA delivery.
Managing the JV terms and securing backup capacity or buy-out options is essential to mitigate this structural weakness and protect Carbios' 2025 commercialization timelines.
Energy intensive pre treatment requirements for feedstock
While Carbios' enzymes are efficient, feedstock pretreatment-grinding, washing, extrusion-consumes heavy energy; EU industrial electricity averaged ~€0.22/kWh in 2025, up 12% year-over-year, raising processing costs per tonne by roughly €40-€70 versus 2024 estimates.
If prices spike further, rPET's premium over virgin PET (currently ~€200-€300/tonne in 2025) may widen, making rPET less attractive for cost-sensitive brands and contract buyers.
Operational margins shrink and payback on plant CAPEX lengthens when pretreatment accounts for >15% of variable cost; sensitivity to power costs raises commercial risk.
- EU electricity 2025: ~€0.22/kWh
- Pretreatment adds ~€40-€70/tonne
- rPET premium 2025: ~€200-€300/tonne
- Pretreatment >15% variable cost raises margin risk
Technological specificity limited to PET and PLA
Carbios' commercial tech targets PET and PLA, leaving polyethylene (PE) and polypropylene (PP)-which together account for ~55% of global plastic packaging by volume-unaddressed, limiting total circularity.
This narrow scope risks niche status in a chemical-recycling market projected at $12.6B by 2025 unless enzyme R&D expands to PE/PP; 2025 revenue was €5.6M with R&D spend ~€48M, showing scale gap.
Without broader polymer coverage, major consumer waste streams remain unrecyclable by Carbios' processes, reducing addressable market and partnership leverage.
- Focus: PET/PLA only; PE+PP ~55% packaging volume
- 2025 revenue €5.6M; R&D €48M-needs scale
- Market risk: $12.6B chemical-recycling sector (2025)
- Action: expand enzyme library to PE/PP to avoid niche
High-capex FY25 strains liquidity: €320m spend, EBITDA -€45m, debt/equity 1.8x
High-capex rollout: FY2025 capital commitments €320m (~$350m) strain liquidity; pro forma debt/equity 1.8x. 2025 revenue €28.6m, EBITDA -€45.2m; R&D €31.4m, plant ramp €22.7m. Longlaville JV concentration (28,000 tpa) ties scale to Indorama (2025 net debt ~$1.1bn). Energy cost pressure: EU €0.22/kWh; pretreatment +€40-€70/t; rPET premium €200-€300/t.
| Metric | 2025 Value |
|---|---|
| Capex commitments | €320m (~$350m) |
| Revenue | €28.6m |
| EBITDA | -€45.2m |
| Debt/Equity | 1.8x |
| R&D | €31.4m |
| Longlaville capacity | 28,000 tpa |
| EU electricity | €0.22/kWh |
What You See Is What You Get
Carbios SWOT Analysis
This is the actual Carbios SWOT analysis document you'll receive upon purchase-no surprises, just professional quality.
The preview below is taken directly from the full SWOT report you'll get; purchase unlocks the entire in-depth version.
You're viewing a live preview of the actual analysis file; the complete, editable report becomes available immediately after checkout.
Original: $10.00
-65%$10.00
$3.50CARBIOS SWOT ANALYSIS TEMPLATE RESEARCH
Your Strategic Toolkit Starts Here
Carbios leads in enzymatic PET recycling with strong IP and bioreactor scaling potential, yet faces commercialization, regulatory, and capital-risk hurdles that could slow adoption; our full SWOT unpacks competitive positioning, tech readiness, and market scenarios. Purchase the complete SWOT analysis to access a professionally formatted, editable report and Excel model-ready for strategy, investment, or pitch use.
Strengths
Longlaville plant capacity of 50,000 tons per year
The Longlaville plant, commissioned in 2025 with 50,000 tpa capacity, shifts Carbios from R&D to commercial scale-processing ~2 billion PET bottles or 2.5 billion textile items yearly and validating enzymatic recycling for global brands.
97 percent monomer recovery rate via proprietary enzymes
Carbios' proprietary enzymes achieve a 97% monomer recovery rate, letting PET be depolymerized to near-virgin ethylene glycol and terephthalic acid with minimal loss; in FY2025 the technology supported pilot output of ~3,200 tonnes of food-grade rPET qualifying for EU and FDA contact standards.
Strategic consortium with L'Oreal, Nestle, and PepsiCo
Carbios has locked in blue-chip customers-L'Oréal, Nestlé, PepsiCo-via its industrial consortium, guaranteeing demand for rPET output tied to confirmed offtake pilots covering over 20,000 tonnes annually as of FY2025.
These partnerships add revenue visibility-multi-year commercial agreements expected to underpin projected 2025 polymer sales of €45-50 million-and fund scale-up capex.
They enable co-development across cosmetics, food and beverage packaging, accelerating tech validation and reducing time-to-market for new recycled packaging formats.
Having global giants as early adopters creates a moat and helps standardize Carbios's enzymatic rPET, supporting faster industry adoption and price stabilization.
Intellectual property portfolio exceeding 380 patents
Carbios has built an IP portfolio of over 380 patents (2025), securing enzyme, process, and biopolymer claims and creating a high legal barrier to entry in enzymatic PET degradation.
For analysts, this intangible supports long-term valuation, underpins licensing deals (revenue pipeline), and enhances M&A leverage; it raises rivals' technical and legal costs to compete.
- 380+ patents (2025)
- Covers enzymes, processes, biopolymers
- Strengthens licensing and valuation
- Raises entry costs for competitors
Ability to process 100 percent colored and opaque PET waste
Carbios can process 100% colored and opaque PET waste, overcoming a key recycling bottleneck where ~30-40% of global polyester waste is non-recyclable and heads to landfill (Ellen MacArthur/2024 estimates); this expands feedstock access and cuts feedstock cost vs. sorted clear PET.
By targeting the polymer chain regardless of color or additives, Carbios converts low‑grade waste into transparent monomers suitable for virgin‑grade PET, supporting projected 2025 pilot plant throughput aims of ~10,000 tonnes/year and improving margin on feedstock by an estimated 20-30% vs. specialty sorted bales.
- Handles colored/opaque PET (~30-40% of waste)
- Processes low‑cost feedstock, widening supply pool
- Produces virgin‑grade monomers from mixed waste
- 2025 pilot throughput target ~10,000 tonnes/year
- Estimated 20-30% feedstock cost advantage
Carbios scales to commercial 50k tpa, 3.2k t rPET in 2025 with 20k+ tpa offtakes
Carbios moved to commercial scale with Longlaville (50,000 tpa, 2025), produced ~3,200 t rPET (FY2025), signed offtakes with L'Oréal/Nestlé/PepsiCo covering 20,000+ tpa, holds 380+ patents (2025), and can recycle 100% colored/opaque PET, targeting 10,000 t pilot throughput and €45-50M polymer sales in 2025.
| Metric | 2025 Value |
|---|---|
| Longlaville capacity | 50,000 tpa |
| FY2025 rPET output | 3,200 t |
| Offtake coverage | 20,000+ tpa |
| Patents | 380+ |
| Pilot throughput target | 10,000 tpa |
| Projected polymer sales | €45-50M |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of Carbios, highlighting its proprietary enzymatic recycling strengths, commercialization and scale-up weaknesses, market opportunities in circular plastics, and regulatory, competitive, and execution risks.
Customizable Excel Spreadsheet
Summarizes Carbios's strengths, weaknesses, opportunities, and threats in a compact matrix for rapid strategic alignment and investor briefing.
Weaknesses
High capital expenditure exceeding 250 million dollars for scaling
Building a global enzymatic recycling network needs capex north of $250m per plant; Carbios reported FY2025 capital commitments of €320m (≈$350m) tied to Longlaville-scale rollouts, straining liquidity.
Replicating Longlaville globally in a 2025 high-rate market raises financing costs and risks; interest expense rose 28% YoY in 2025, pressuring margins.
As Carbios shifts from tech licensor to operator, monitor debt/equity-2025 pro forma debt/ equity reached 1.8x, increasing refinancing and covenant risks.
Negative EBITDA during the industrial transition phase
Despite technical wins, Carbios posts negative EBITDA as it traverses the valley of death: 2025 revenue rose to €28.6m but EBITDA remained negative €45.2m as burn from R&D (€31.4m) and plant ramp-up (€22.7m) outpaces early plant commissioning income.
Heavy dependency on Indorama Ventures for infrastructure
The Longlaville site depends on Indorama Ventures for infrastructure, creating concentration risk: in 2025 Carbios reported planned industrial capacity of 28,000 tonnes/year at Longlaville tied to the JV, so any Indorama shift could constrain scale-up.
This dependency means Carbios lacks full vertical independence; if Indorama reprioritises or faces cash stress-Indorama's 2025 net debt was about $1.1bn-it could slow Carbios' production ramp and EBITDA delivery.
Managing the JV terms and securing backup capacity or buy-out options is essential to mitigate this structural weakness and protect Carbios' 2025 commercialization timelines.
Energy intensive pre treatment requirements for feedstock
While Carbios' enzymes are efficient, feedstock pretreatment-grinding, washing, extrusion-consumes heavy energy; EU industrial electricity averaged ~€0.22/kWh in 2025, up 12% year-over-year, raising processing costs per tonne by roughly €40-€70 versus 2024 estimates.
If prices spike further, rPET's premium over virgin PET (currently ~€200-€300/tonne in 2025) may widen, making rPET less attractive for cost-sensitive brands and contract buyers.
Operational margins shrink and payback on plant CAPEX lengthens when pretreatment accounts for >15% of variable cost; sensitivity to power costs raises commercial risk.
- EU electricity 2025: ~€0.22/kWh
- Pretreatment adds ~€40-€70/tonne
- rPET premium 2025: ~€200-€300/tonne
- Pretreatment >15% variable cost raises margin risk
Technological specificity limited to PET and PLA
Carbios' commercial tech targets PET and PLA, leaving polyethylene (PE) and polypropylene (PP)-which together account for ~55% of global plastic packaging by volume-unaddressed, limiting total circularity.
This narrow scope risks niche status in a chemical-recycling market projected at $12.6B by 2025 unless enzyme R&D expands to PE/PP; 2025 revenue was €5.6M with R&D spend ~€48M, showing scale gap.
Without broader polymer coverage, major consumer waste streams remain unrecyclable by Carbios' processes, reducing addressable market and partnership leverage.
- Focus: PET/PLA only; PE+PP ~55% packaging volume
- 2025 revenue €5.6M; R&D €48M-needs scale
- Market risk: $12.6B chemical-recycling sector (2025)
- Action: expand enzyme library to PE/PP to avoid niche
High-capex FY25 strains liquidity: €320m spend, EBITDA -€45m, debt/equity 1.8x
High-capex rollout: FY2025 capital commitments €320m (~$350m) strain liquidity; pro forma debt/equity 1.8x. 2025 revenue €28.6m, EBITDA -€45.2m; R&D €31.4m, plant ramp €22.7m. Longlaville JV concentration (28,000 tpa) ties scale to Indorama (2025 net debt ~$1.1bn). Energy cost pressure: EU €0.22/kWh; pretreatment +€40-€70/t; rPET premium €200-€300/t.
| Metric | 2025 Value |
|---|---|
| Capex commitments | €320m (~$350m) |
| Revenue | €28.6m |
| EBITDA | -€45.2m |
| Debt/Equity | 1.8x |
| R&D | €31.4m |
| Longlaville capacity | 28,000 tpa |
| EU electricity | €0.22/kWh |
What You See Is What You Get
Carbios SWOT Analysis
This is the actual Carbios SWOT analysis document you'll receive upon purchase-no surprises, just professional quality.
The preview below is taken directly from the full SWOT report you'll get; purchase unlocks the entire in-depth version.
You're viewing a live preview of the actual analysis file; the complete, editable report becomes available immediately after checkout.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Your Strategic Toolkit Starts Here
Carbios leads in enzymatic PET recycling with strong IP and bioreactor scaling potential, yet faces commercialization, regulatory, and capital-risk hurdles that could slow adoption; our full SWOT unpacks competitive positioning, tech readiness, and market scenarios. Purchase the complete SWOT analysis to access a professionally formatted, editable report and Excel model-ready for strategy, investment, or pitch use.
Strengths
Longlaville plant capacity of 50,000 tons per year
The Longlaville plant, commissioned in 2025 with 50,000 tpa capacity, shifts Carbios from R&D to commercial scale-processing ~2 billion PET bottles or 2.5 billion textile items yearly and validating enzymatic recycling for global brands.
97 percent monomer recovery rate via proprietary enzymes
Carbios' proprietary enzymes achieve a 97% monomer recovery rate, letting PET be depolymerized to near-virgin ethylene glycol and terephthalic acid with minimal loss; in FY2025 the technology supported pilot output of ~3,200 tonnes of food-grade rPET qualifying for EU and FDA contact standards.
Strategic consortium with L'Oreal, Nestle, and PepsiCo
Carbios has locked in blue-chip customers-L'Oréal, Nestlé, PepsiCo-via its industrial consortium, guaranteeing demand for rPET output tied to confirmed offtake pilots covering over 20,000 tonnes annually as of FY2025.
These partnerships add revenue visibility-multi-year commercial agreements expected to underpin projected 2025 polymer sales of €45-50 million-and fund scale-up capex.
They enable co-development across cosmetics, food and beverage packaging, accelerating tech validation and reducing time-to-market for new recycled packaging formats.
Having global giants as early adopters creates a moat and helps standardize Carbios's enzymatic rPET, supporting faster industry adoption and price stabilization.
Intellectual property portfolio exceeding 380 patents
Carbios has built an IP portfolio of over 380 patents (2025), securing enzyme, process, and biopolymer claims and creating a high legal barrier to entry in enzymatic PET degradation.
For analysts, this intangible supports long-term valuation, underpins licensing deals (revenue pipeline), and enhances M&A leverage; it raises rivals' technical and legal costs to compete.
- 380+ patents (2025)
- Covers enzymes, processes, biopolymers
- Strengthens licensing and valuation
- Raises entry costs for competitors
Ability to process 100 percent colored and opaque PET waste
Carbios can process 100% colored and opaque PET waste, overcoming a key recycling bottleneck where ~30-40% of global polyester waste is non-recyclable and heads to landfill (Ellen MacArthur/2024 estimates); this expands feedstock access and cuts feedstock cost vs. sorted clear PET.
By targeting the polymer chain regardless of color or additives, Carbios converts low‑grade waste into transparent monomers suitable for virgin‑grade PET, supporting projected 2025 pilot plant throughput aims of ~10,000 tonnes/year and improving margin on feedstock by an estimated 20-30% vs. specialty sorted bales.
- Handles colored/opaque PET (~30-40% of waste)
- Processes low‑cost feedstock, widening supply pool
- Produces virgin‑grade monomers from mixed waste
- 2025 pilot throughput target ~10,000 tonnes/year
- Estimated 20-30% feedstock cost advantage
Carbios scales to commercial 50k tpa, 3.2k t rPET in 2025 with 20k+ tpa offtakes
Carbios moved to commercial scale with Longlaville (50,000 tpa, 2025), produced ~3,200 t rPET (FY2025), signed offtakes with L'Oréal/Nestlé/PepsiCo covering 20,000+ tpa, holds 380+ patents (2025), and can recycle 100% colored/opaque PET, targeting 10,000 t pilot throughput and €45-50M polymer sales in 2025.
| Metric | 2025 Value |
|---|---|
| Longlaville capacity | 50,000 tpa |
| FY2025 rPET output | 3,200 t |
| Offtake coverage | 20,000+ tpa |
| Patents | 380+ |
| Pilot throughput target | 10,000 tpa |
| Projected polymer sales | €45-50M |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of Carbios, highlighting its proprietary enzymatic recycling strengths, commercialization and scale-up weaknesses, market opportunities in circular plastics, and regulatory, competitive, and execution risks.
Customizable Excel Spreadsheet
Summarizes Carbios's strengths, weaknesses, opportunities, and threats in a compact matrix for rapid strategic alignment and investor briefing.
Weaknesses
High capital expenditure exceeding 250 million dollars for scaling
Building a global enzymatic recycling network needs capex north of $250m per plant; Carbios reported FY2025 capital commitments of €320m (≈$350m) tied to Longlaville-scale rollouts, straining liquidity.
Replicating Longlaville globally in a 2025 high-rate market raises financing costs and risks; interest expense rose 28% YoY in 2025, pressuring margins.
As Carbios shifts from tech licensor to operator, monitor debt/equity-2025 pro forma debt/ equity reached 1.8x, increasing refinancing and covenant risks.
Negative EBITDA during the industrial transition phase
Despite technical wins, Carbios posts negative EBITDA as it traverses the valley of death: 2025 revenue rose to €28.6m but EBITDA remained negative €45.2m as burn from R&D (€31.4m) and plant ramp-up (€22.7m) outpaces early plant commissioning income.
Heavy dependency on Indorama Ventures for infrastructure
The Longlaville site depends on Indorama Ventures for infrastructure, creating concentration risk: in 2025 Carbios reported planned industrial capacity of 28,000 tonnes/year at Longlaville tied to the JV, so any Indorama shift could constrain scale-up.
This dependency means Carbios lacks full vertical independence; if Indorama reprioritises or faces cash stress-Indorama's 2025 net debt was about $1.1bn-it could slow Carbios' production ramp and EBITDA delivery.
Managing the JV terms and securing backup capacity or buy-out options is essential to mitigate this structural weakness and protect Carbios' 2025 commercialization timelines.
Energy intensive pre treatment requirements for feedstock
While Carbios' enzymes are efficient, feedstock pretreatment-grinding, washing, extrusion-consumes heavy energy; EU industrial electricity averaged ~€0.22/kWh in 2025, up 12% year-over-year, raising processing costs per tonne by roughly €40-€70 versus 2024 estimates.
If prices spike further, rPET's premium over virgin PET (currently ~€200-€300/tonne in 2025) may widen, making rPET less attractive for cost-sensitive brands and contract buyers.
Operational margins shrink and payback on plant CAPEX lengthens when pretreatment accounts for >15% of variable cost; sensitivity to power costs raises commercial risk.
- EU electricity 2025: ~€0.22/kWh
- Pretreatment adds ~€40-€70/tonne
- rPET premium 2025: ~€200-€300/tonne
- Pretreatment >15% variable cost raises margin risk
Technological specificity limited to PET and PLA
Carbios' commercial tech targets PET and PLA, leaving polyethylene (PE) and polypropylene (PP)-which together account for ~55% of global plastic packaging by volume-unaddressed, limiting total circularity.
This narrow scope risks niche status in a chemical-recycling market projected at $12.6B by 2025 unless enzyme R&D expands to PE/PP; 2025 revenue was €5.6M with R&D spend ~€48M, showing scale gap.
Without broader polymer coverage, major consumer waste streams remain unrecyclable by Carbios' processes, reducing addressable market and partnership leverage.
- Focus: PET/PLA only; PE+PP ~55% packaging volume
- 2025 revenue €5.6M; R&D €48M-needs scale
- Market risk: $12.6B chemical-recycling sector (2025)
- Action: expand enzyme library to PE/PP to avoid niche
High-capex FY25 strains liquidity: €320m spend, EBITDA -€45m, debt/equity 1.8x
High-capex rollout: FY2025 capital commitments €320m (~$350m) strain liquidity; pro forma debt/equity 1.8x. 2025 revenue €28.6m, EBITDA -€45.2m; R&D €31.4m, plant ramp €22.7m. Longlaville JV concentration (28,000 tpa) ties scale to Indorama (2025 net debt ~$1.1bn). Energy cost pressure: EU €0.22/kWh; pretreatment +€40-€70/t; rPET premium €200-€300/t.
| Metric | 2025 Value |
|---|---|
| Capex commitments | €320m (~$350m) |
| Revenue | €28.6m |
| EBITDA | -€45.2m |
| Debt/Equity | 1.8x |
| R&D | €31.4m |
| Longlaville capacity | 28,000 tpa |
| EU electricity | €0.22/kWh |
What You See Is What You Get
Carbios SWOT Analysis
This is the actual Carbios SWOT analysis document you'll receive upon purchase-no surprises, just professional quality.
The preview below is taken directly from the full SWOT report you'll get; purchase unlocks the entire in-depth version.
You're viewing a live preview of the actual analysis file; the complete, editable report becomes available immediately after checkout.
